Stem Cell Reviews and Reports

, Volume 9, Issue 3, pp 303–312

Thymosin β4 and Cardiac Regeneration: Are We Missing a Beat?

  • David C. Gajzer
  • Jerome Balbin
  • Hina W. Chaudhry
Article

DOI: 10.1007/s12015-012-9378-3

Cite this article as:
Gajzer, D.C., Balbin, J. & Chaudhry, H.W. Stem Cell Rev and Rep (2013) 9: 303. doi:10.1007/s12015-012-9378-3

Abstract

Epicardial resident stem cells are known to differentiate into cardiomyocytes during cardiac development, amongst other cell types. Whether epicardium-derived progenitor cells (EPDCs) retain this plasticity in the adult heart has been the topic of heated scientific debate. Priming with thymosin beta 4, a peptide which has been suggested to be critical for cardiac development and to have cardio-protective properties, was recently shown to induce differentiation of EPDCs into cardiomyocytes in a small animal model of myocardial infarction. This finding is in stark contrast to another recent study in which thymosin beta 4 treatment following myocardial infarction did not induce cardiomyocyte differentiation of EPDCs. While EPDCs seem to exhibit overall cardio-protective effects on the heart following myocardial infarction, they have not been shown to differentiate into cardiomyocytes in a clinically relevant setting. It will be important to understand why the ability of one therapeutic agent to induce cardiomyocyte differentiation of EPDCs seemingly depends on a single variable, i.e. the time of administration. Furthermore, in light of a recent report, it appears that thymosin beta 4 may be dispensable for cardiac development.

Keywords

Stem cells Progenitor cells Cardiac development Ischemic biology–basic studies Myogenesis 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • David C. Gajzer
    • 1
  • Jerome Balbin
    • 1
  • Hina W. Chaudhry
    • 1
  1. 1.Cardiovascular Regenerative Medicine, Cardiovascular Research Center, Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations